Unlock Streamlined Care with
HEPZATO KIT™ ACCESS 360
With HEPZATO KIT™ ACCESS 360, you’re never alone. We’re here to unlock financial relief, personalized guidance, and a smoother treatment journey—so you can focus on what matters most.
INDICATION AND USAGE
HEPZATO (melphalan) is a prescription drug for liver-directed treatment for adults with uveal melanoma (a certain type of eye cancer) that has spread to the liver but can’t be removed with surgery. This treatment is for cases where less than half of the liver is affected, and the cancer hasn’t spread to other parts of the body, or it has only spread to the bones, lymph nodes, skin, or lungs where it can be treated with surgery or radiation.
HEPZATO KIT uses a special delivery system to send the medicine HEPZATO (melphalan) directly to the liver artery and a filtration system to reduce the amount of melphalan in the blood before it goes back into the rest of the body.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about HEPZATO?
- HEPZATO may cause serious problems like bleeding, liver damage, and blood clots. You may need to stop taking blood thinners or blood pressure medicine before treatment with HEPZATO KIT.
- HEPZATO can only be used through a special program called the HEPZATO KIT REMS (Risk Evaluation and Mitigation Strategies) Program.
- HEPZATO can lower the number of blood cells, leading to serious infections, bleeding, or anemia. Tell your doctor right away if you have a fever, bruising, or bleeding.
Do not take HEPZATO if you have:
- active brain cancer or brain spots that are likely to bleed
- liver failure, high blood pressure in the liver, or known risk of bleeding in the liver
- surgery or medical treatment of the liver in the past 4 weeks
- blood clotting problems that can’t be fixed
- inability to safely undergo general anesthesia, including heart problems like unstable or severe chest pain, heart attack, worsening or new heart failure, serious irregular heartbeats, or severe heart valve disease
- history of allergies or known reactions to melphalan or any part of the HEPZATO KIT, including natural rubber latex, heparin, or severe reactions to iodine contrast not controlled by antihistamines and steroids
HEPZATO may cause serious side effects including:
Secondary malignancies, HEPZATO could have a long-term risk of causing another type of cancer.
HEPZATO can cause serious birth defects if taken during pregnancy. Females who can become pregnant should use effective birth control during treatment with HEPZATO and for 6 months after the last dose. Contact your doctor if you become pregnant or think you might be pregnant while taking HEPZATO. Males with partners who can become pregnant should use effective birth control during treatment with HEPZATO and for 3 months after the last dose.
Infertility, HEPZATO has been reported to cause infertility in females and males.
Do not breastfeed during treatment with HEPZATO and for one week after the last dose.
The most common side effects of HEPZATO are: low platelets, tiredness, low red blood cells, nausea, muscle and bone pain, low white blood cells, belly pain, low white blood cells, vomiting, high liver enzymes, longer blood clotting time, and shortness of breath.
Please see full Prescribing Information, including Boxed Warning.
Call your healthcare provider for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Delcath at 1-833-632-0458 and www.Delcath.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
Your Key to Connected Care
At Delcath Systems, we believe that accessing treatment should be simple and stress-free. HEPZATO KIT™ ACCESS 360 is designed to help unlock financial relief, personalized support, and a smoother treatment journey—so you can focus on what truly matters.
Unlocking Financial Relief
The cost of treatment shouldn’t be a barrier. Our copay assistance program can help ease the financial burden, ensuring you can move forward with confidence. Eligible individuals can receive the Hepzato Kit™ for as little as $0, with a maximum benefit of $10,000 per calendar year.
Guidance You Can Trust, From Start to Finish
With a dedicated Clinical Navigator by your side, you’ll have expert support to answer questions, coordinate care, and help navigate the process—so you’re never left searching for answers. From initial consultation to post-treatment care, we’re with you every step of the way.
Clearing the Way to Treatment
We’re here to remove obstacles and streamline access to care. From navigating insurance approvals to coordinating with treatment centers, we’ll make sure financial or logistical challenges don’t stand in your way.
Personalized Support, A Secure Path Forward
Every patient’s journey is unique, and so is our approach. We work to match support to your specific needs, ensuring you have the guidance, financial assistance, and care coordination that fit your treatment plan.
Step Forward with Confidence
With HEPZATO KIT Access 360, you’re never alone. We’re here to help open doors, provide support, and secure the care you deserve—every step of the way.
Eligibility Requirements
You may be eligible for the HEPZATO KIT Access 360 Copay Assistance Program if you are:
- Commercially insured
- A resident of, and treated with the Hepzato Kit™ in, the US
- Receiving treatment at a Delcath REMS-certified facility (Healthcare Setting Locator Site)
†This is not insurance. Subject to change or discontinuation by Delcath at any time.
Start Your Journey with HEPZATO KIT™ Access 360
Take the first step toward financial relief and personalized support today. Enroll NowWhat is HEPZATO and HEPZATO KIT?
HEPZATO (melphalan) is a prescription drug for liver-directed treatment for adults with uveal melanoma (a certain type of eye cancer) that has spread to the liver but can’t be removed with surgery. This treatment is for cases where less than half of the liver is affected, and the cancer hasn’t spread to other parts of the body, or it has only spread to the bones, lymph nodes, skin, or lungs where it can be treated with surgery or radiation.
HEPZATO KIT uses a special delivery system to send the medicine HEPZATO (melphalan) directly to the liver artery and a filtration system to reduce the amount of melphalan in the blood before it goes back into the rest of the body.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about HEPZATO?
- HEPZATO may cause serious problems like bleeding, liver damage, and blood clots. You may need to stop taking blood thinners or blood pressure medicine before treatment with HEPZATO KIT.
- HEPZATO can only be used through a special program called the HEPZATO KIT REMS (Risk Evaluation and Mitigation Strategies) Program.
- HEPZATO can lower the number of blood cells, leading to serious infections, bleeding, or anemia. Tell your doctor right away if you have a fever, bruising, or bleeding.
Do not take HEPZATO if you have:
- active brain cancer or brain spots that are likely to bleed
- liver failure, high blood pressure in the liver, or known risk of bleeding in the liver
- surgery or medical treatment of the liver in the past 4 weeks
- blood clotting problems that can’t be fixed
- inability to safely undergo general anesthesia, including heart problems like unstable or severe chest pain, heart attack, worsening or new heart failure, serious irregular heartbeats, or severe heart valve disease
- history of allergies or known reactions to melphalan or any part of the HEPZATO KIT, including natural rubber latex, heparin, or severe reactions to iodine contrast not controlled by antihistamines and steroids
HEPZATO may cause serious side effects including:
Secondary malignancies, HEPZATO could have a long-term risk of causing another type of cancer.
HEPZATO can cause serious birth defects if taken during pregnancy. Females who can become pregnant should use effective birth control during treatment with HEPZATO and for 6 months after the last dose. Contact your doctor if you become pregnant or think you might be pregnant while taking HEPZATO. Males with partners who can become pregnant should use effective birth control during treatment with HEPZATO and for 3 months after the last dose.
Infertility, HEPZATO has been reported to cause infertility in females and males.
Do not breastfeed during treatment with HEPZATO and for one week after the last dose.
The most common side effects of HEPZATO are: low platelets, tiredness, low red blood cells, nausea, muscle and bone pain, low white blood cells, belly pain, low white blood cells, vomiting, high liver enzymes, longer blood clotting time, and shortness of breath.
Please see full Prescribing Information, including Boxed Warning.
Call your healthcare provider for medical advice about side effects. To report SUSPECTED ADVERSE REACTIONS, contact Delcath at 1-833-632-0458 and www.Delcath.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.